rnf-5 Antibody

What is RNF5 and what cellular functions does it regulate?

RNF5 (RING finger protein 5, also known as RMA1, NG2, or G16) is a 180 amino acid membrane-bound ubiquitin ligase characterized by a RING-type zinc finger motif that enables binding of two zinc atoms. This motif is crucial for its function in the ubiquitination pathway, a key mechanism in protein degradation. RNF5 primarily regulates cell motility by targeting paxillin ubiquitination and altering the distribution and localization of paxillin in cytoplasm and cell focal adhesions. This modulation affects the ability of paxillin to recruit signaling molecules to focal adhesions, thereby influencing cellular signaling and movement . Additionally, RNF5 plays significant roles in protein localization and cancer progression, with recent studies highlighting its importance in inhibiting antiviral innate immunity by promoting the ubiquitination and degradation of STING and MAVS, which are essential adaptor proteins in immune response pathways .

What are the key specifications of commonly used anti-RNF5 antibodies?

Anti-RNF5 antibodies are available in various formulations optimized for different experimental applications. The widely used Anti-RNF5 [22B3] monoclonal antibody exhibits the following specifications:

This antibody is available in both non-conjugated forms and various conjugated formats, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates .

How can researchers validate the specificity of anti-RNF5 antibodies?

Antibody validation is critical for ensuring experimental reliability. For anti-RNF5 antibodies, several validation approaches are recommended:

• Western blotting using positive control lysates from cells known to express RNF5 (human and mouse cell lines) alongside negative controls (RNF5 knockout cells).

• Immunoprecipitation followed by mass spectrometry to confirm the identity of the pulled-down protein.

• Assessment of cross-reactivity with related RING finger proteins to ensure specificity.

• Validation through knockout models, such as the CRISPR-Cas9 RNF5 knockout cells described in the literature, where guide RNA targeting exon 1 of RNF5 has been successfully employed .

When validating through Western blotting, researchers should observe a band at approximately 20 kDa corresponding to the 180 amino acid RNF5 protein. Signal reduction or elimination in knockout samples provides strong evidence of antibody specificity .

How do RNF5 antibodies contribute to studying antiviral immunity mechanisms?

RNF5 antibodies have become instrumental in elucidating the complex role of RNF5 in antiviral immunity. Recent studies have revealed that RNF5 acts as a negative regulator of antiviral responses by targeting key signaling proteins for degradation. Specifically, RNF5 promotes the K48-linked polyubiquitination of STING, targeting it for proteasomal degradation and thereby limiting the duration and magnitude of STING-dependent immune responses. Similarly, RNF5 interacts with MAVS, catalyzing its K48-linked ubiquitination at K362 and K461 (in human cells), which leads to proteasome-dependent degradation .

Researchers utilize RNF5 antibodies to:

• Assess endogenous RNF5 expression levels during viral infections, revealing temporal regulation patterns.

• Perform co-immunoprecipitation experiments to identify interaction partners of RNF5, which has revealed progressively strengthened association with MAVS at 6-12 hours post-infection.

• Track changes in RNF5 localization during viral infection using immunofluorescence microscopy.

• Evaluate how viral infections might modulate RNF5 expression or activity as part of immune evasion strategies.

These applications have contributed to our understanding of how RNF5 abundance is delicately regulated by both host factors and viruses, with host factors restricting RNF5-mediated ubiquitination to maintain STING or MAVS stability, while viruses have developed strategies to hijack RNF5 to degrade immune proteins .

What role does RNF5 play in SARS-CoV-2 infection, and how can antibodies help investigate this?

Recent investigations have uncovered the multifaceted roles of RNF5 in the SARS-CoV-2 life cycle, particularly in viral assembly, budding, and release. RNF5 has been found to mediate K63-linked ubiquitination of the SARS-CoV-2 M protein at the K15 site, which promotes the interaction between M's N-terminal domain and the E protein. This interaction stabilizes the M-E complex on the membrane, which is critical for viral assembly and budding. Additionally, this ubiquitin modification facilitates the trafficking of M from the Golgi apparatus to autophagosomes, facilitating virion release .

Anti-RNF5 antibodies enable researchers to:

• Detect changes in RNF5 expression levels during SARS-CoV-2 infection.

• Identify viral-host protein interactions through co-immunoprecipitation studies.

• Visualize the co-localization of RNF5 with viral proteins in infected cells.

• Assess the effects of RNF5 knockdown or inhibition on viral replication, assembly, and release.

These studies have positioned RNF5 as an emerging target for antiviral therapy, as it facilitates virion release by mediating the ubiquitin modification of SARS-CoV-2 M protein. Inhibiting RNF5 could potentially disrupt this process and impair viral replication .

How can researchers study the opposing roles of RNF5 in different species and contexts?

Interestingly, while human RNF5 generally inhibits antiviral immunity, recent studies have shown that swine RNF5 (sRNF5) positively regulates the antiviral activity of swine IFITM1 (sIFITM1) by mediating the degradation of swine ABHD16A (sABHD16A). This highlights the species-specific and context-dependent roles of RNF5 .

To investigate these opposing functions, researchers can:

• Use species-specific anti-RNF5 antibodies to compare expression patterns and interactions across different organisms.

• Generate knockout models in different species, such as the sRNF5 knockout PK15 cells created using CRISPR-Cas9 technology with guide RNA targeting exon 1 of swine RNF5.

• Perform comparative interactome analyses to identify species-specific binding partners.

• Conduct cross-species complementation experiments to determine if RNF5 from one species can functionally replace RNF5 from another species.

This approach has already yielded valuable insights, such as the finding that sRNF5 knockout in PK15 cells affects the antiviral activity of sIFITM1, demonstrating for the first time that sRNF5 positively regulates the antiviral function of sIFITM1 by mediating the degradation of sABHD16A .

What are the optimal conditions for using anti-RNF5 antibodies in Western blotting?

To achieve optimal results when using anti-RNF5 antibodies for Western blotting, researchers should consider the following protocol guidelines:

• Sample preparation: Lyse cells in a buffer containing protease inhibitors to prevent degradation of RNF5. Include 1-2% NP-40 or Triton X-100 to effectively solubilize membrane-associated RNF5.

• Gel electrophoresis: Use 12-15% SDS-PAGE gels to provide optimal resolution for the 20 kDa RNF5 protein.

• Transfer conditions: Transfer to PVDF membrane at 100V for 60-90 minutes in standard Tris-glycine buffer with 20% methanol.

• Blocking: Block membranes in 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute anti-RNF5 antibody (such as the 22B3 clone) to 1:500-1:1000 in blocking buffer and incubate overnight at 4°C.

• Secondary antibody: Use appropriate HRP-conjugated secondary antibody (anti-mouse IgG for the 22B3 clone) at 1:5000 dilution for 1 hour at room temperature.

• Detection: Use enhanced chemiluminescence (ECL) reagents for visualization, with exposure times typically ranging from 30 seconds to 5 minutes.

When interpreting results, researchers should expect to detect RNF5 as a band around 20 kDa, though post-translational modifications may affect the observed molecular weight. Including positive and negative controls, such as RNF5-overexpressing cells and RNF5 knockout cells, is essential for validating specificity .

How can researchers generate and validate RNF5 knockout models?

Generation of RNF5 knockout models is a valuable approach for studying RNF5 function. Based on published methodologies, the following protocol has proven effective:

• Guide RNA design: Design guide RNA targeting exon 1 of RNF5 (example from swine RNF5: 5′-GAAGGGCCAAACCGCGAGCG-3′).

• Primer annealing: Anneal primers through 5-minute boiling water bath treatment followed by natural cooling to room temperature.

• Vector cloning: Clone the annealed primer into a LentiCRISPRv2-puro linearized vector through the BsmbI site.

• Cell transfection: Transfect target cells with the recombination plasmid or control vector using Lipofectamine 3000 or similar transfection reagent.

• Selection: Add puromycin dihydrochloride (2 μg/ml) 24 hours after transfection and continue selection for 21 days.

• Monoclonal isolation: Obtain monoclonal cells using the limited dilution culture method.

• Validation: Confirm knockout efficiency via Western blotting using validated anti-RNF5 antibodies.

Additional validation steps may include:

• Genomic DNA sequencing to confirm mutations in the target region

• RT-PCR to assess mRNA levels

• Functional assays to confirm the loss of RNF5-mediated activities, such as changes in ubiquitination patterns of known substrates

What techniques are most effective for studying RNF5-mediated ubiquitination?

Investigating RNF5-mediated ubiquitination requires specialized techniques to detect and characterize ubiquitin linkages and substrate modifications. The following approaches have proven effective:

• Ubiquitination assays: Transfect cells with HA-tagged ubiquitin, RNF5, and the substrate of interest, followed by immunoprecipitation under denaturing conditions to disrupt non-covalent interactions.

• Linkage-specific analysis: Use antibodies that recognize specific ubiquitin linkages (K48-linked for proteins targeted for degradation, K63-linked for signaling functions) to determine the type of ubiquitination mediated by RNF5.

• Mass spectrometry: Identify ubiquitination sites on substrates through proteomic analysis, which has been successfully used to identify K362 and K461 on MAVS as RNF5 ubiquitination sites.

• In vitro ubiquitination assays: Reconstitute the ubiquitination reaction using purified components (E1, E2, RNF5, ubiquitin, ATP, and the substrate) to directly assess RNF5's catalytic activity.

• Proximity ligation assays: Detect protein-protein interactions between RNF5 and its substrates in situ, providing spatial information about where these interactions occur within cells.

When studying RNF5's role in viral processes, researchers should consider the temporal dynamics of RNF5-substrate interactions. For example, co-immunoprecipitation experiments have shown a progressively strengthened association between RNF5 and MAVS at 6-12 hours post-infection, suggesting an early stage regulation that differs from that of other ubiquitin ligases .

How is RNF5 implicated in cancer progression and what methodologies can assess this relationship?

RNF5 has been associated with cancer progression, particularly in breast cancer, where its overexpression has been linked to disease advancement. Conversely, reduced expression levels have been observed in muscular disorders, highlighting its diverse roles in different pathological contexts .

Researchers investigating RNF5's role in cancer can employ these methodologies:

• Immunohistochemical analysis: Use anti-RNF5 antibodies to assess expression levels in tumor tissues compared to adjacent normal tissues. This can be correlated with clinicopathological features and patient outcomes.

• Cell line models: Compare RNF5 expression across cancer cell lines with varying degrees of aggressiveness, and assess the effects of RNF5 knockdown or overexpression on proliferation, migration, and invasion.

• Xenograft studies: Evaluate the impact of RNF5 modulation on tumor growth and metastasis in vivo.

• Mechanistic investigations: Identify cancer-relevant substrates of RNF5 and determine how their ubiquitination affects oncogenic signaling pathways.

• Acute myeloid leukemia (AML) models: Recent studies have begun to explore RNF5's role in determining AML characteristics, suggesting broader implications in hematological malignancies beyond solid tumors .

These approaches can help clarify RNF5's context-dependent roles in cancer and potentially identify subsets of patients who might benefit from therapies targeting RNF5 or its regulated pathways.

What are the therapeutic implications of targeting RNF5 in viral infections?

Given RNF5's emerging role in viral pathogenesis, particularly its involvement in SARS-CoV-2 replication, targeting RNF5 represents a promising antiviral strategy. Several therapeutic approaches warrant investigation:

• Small molecule inhibitors: Develop compounds that disrupt RNF5's ubiquitin ligase activity, potentially preventing the degradation of antiviral factors like STING and MAVS.

• Peptide-based inhibitors: Design peptides that interfere with the interaction between RNF5 and its viral or host substrates.

• RNA interference: Use siRNA or shRNA to downregulate RNF5 expression, potentially enhancing antiviral immunity.

• PROTAC (Proteolysis Targeting Chimera) technology: Create bifunctional molecules that can target RNF5 for degradation by the proteasome.

• Viral protein interaction blockers: Develop compounds that prevent viral proteins from hijacking RNF5 to degrade immune factors.

The therapeutic potential of targeting RNF5 is highlighted by its role in mediating the K63-linked ubiquitination of SARS-CoV-2 M protein, which promotes viral assembly, budding, and release. Inhibiting this interaction could disrupt multiple stages of the viral life cycle, making RNF5 an attractive target for broad-spectrum antiviral development .

How do species-specific differences in RNF5 function impact therapeutic development?

The discovery that swine RNF5 (sRNF5) positively regulates antiviral immunity, in contrast to human RNF5's inhibitory role, highlights important species-specific differences that must be considered in therapeutic development. These differences raise several methodological considerations:

• Species-specific assays: Develop separate experimental systems for evaluating RNF5 function in different species, avoiding cross-species extrapolation.

• Comparative structural biology: Analyze the structural differences between human and swine RNF5 that might account for their opposing functions.

• Domain-swapping experiments: Create chimeric RNF5 proteins combining domains from different species to identify the regions responsible for functional differences.

• Target validation: Ensure that therapeutic targeting of RNF5 produces the desired effect across species, particularly important for zoonotic diseases that affect multiple hosts.

• Differential substrate identification: Compare the substrates of RNF5 across species to understand the molecular basis for functional divergence.

These species-specific considerations are critical for developing therapeutics targeting RNF5, as interventions designed based on human RNF5 biology might have opposite effects in animal models or zoonotic disease reservoirs .

How can researchers address common challenges when using anti-RNF5 antibodies?

Researchers working with anti-RNF5 antibodies may encounter several technical challenges. Here are evidence-based solutions to common problems:

• Poor signal strength:

  • Increase antibody concentration or incubation time

  • Enhance protein extraction by using buffers containing 1-2% NP-40 or Triton X-100 to effectively solubilize membrane-associated RNF5

  • Use signal enhancement systems like tyramide signal amplification

• High background:

  • Increase blocking time or concentration (use 5% BSA instead of milk for phospho-specific detection)

  • Add 0.1-0.3% Tween-20 to washing buffers

  • Extend washing steps (5 washes of 5 minutes each)

  • Pre-absorb antibody with cell lysate from RNF5 knockout cells

• Multiple bands:

  • Verify band identity using positive controls and RNF5 knockout samples

  • Consider post-translational modifications or splice variants

  • Use more stringent denaturing conditions to disrupt protein complexes

• Inconsistent results:

  • Standardize lysate preparation protocols

  • Ensure consistent protein loading (verified by housekeeping protein detection)

  • Maintain consistent transfer conditions across experiments

• Poor immunoprecipitation efficiency:

  • Pre-clear lysates with protein G beads before immunoprecipitation

  • Optimize antibody-to-lysate ratio

  • Consider crosslinking the antibody to beads to prevent heavy chain interference in subsequent Western blotting

What controls should be incorporated when studying RNF5 ubiquitination activity?

When investigating RNF5-mediated ubiquitination, appropriate controls are essential for result validation and interpretation:

• Negative controls:

  • RNF5 knockout or knockdown cells

  • Catalytically inactive RNF5 mutant (mutation in the RING domain)

  • Substrate mutant with ubiquitination sites mutated (e.g., K362R and K461R mutations in MAVS)

• Positive controls:

  • Cells overexpressing wild-type RNF5

  • Known RNF5 substrates (STING, MAVS, paxillin)

  • System validation using a well-characterized E3 ligase-substrate pair

• Ubiquitination specificity controls:

  • Ubiquitin mutants (K48R, K63R) to confirm linkage specificity

  • Deubiquitinating enzyme (DUB) treatment to verify ubiquitination

  • Proteasome inhibitors (for K48-linked substrates) or lysosome inhibitors (for K63-linked substrates) to stabilize ubiquitinated proteins

• Temporal controls:

  • Time-course experiments to capture the dynamic nature of ubiquitination

  • Synchronized infection models to correlate RNF5 activity with specific stages of viral life cycles

• Subcellular localization controls:

  • Organelle markers to confirm the location of RNF5-substrate interactions

  • Fractionation controls to verify separation of membrane-bound and cytosolic components

What emerging technologies could enhance our understanding of RNF5 function?

Several cutting-edge technologies hold promise for advancing RNF5 research:

• CRISPR-based screening: Genome-wide CRISPR screens can identify novel regulators of RNF5 expression or activity, as well as additional substrates and interacting partners.

• Proximity labeling proteomics: BioID or APEX2-based approaches can map the RNF5 interactome in different cellular compartments and under various conditions, including viral infection.

• Single-cell analysis: Single-cell RNA-seq and proteomics can reveal cell type-specific functions of RNF5 and heterogeneity in its expression patterns.

• Structural biology advances: Cryo-EM and X-ray crystallography of RNF5 in complex with its substrates can provide insights into the molecular basis of substrate recognition.

• Live-cell imaging: FRET-based sensors for ubiquitination can enable real-time monitoring of RNF5 activity in living cells.

• Organoids and patient-derived models: These systems can provide more physiologically relevant contexts for studying RNF5 function in disease states.

These technologies could help resolve current knowledge gaps, such as the full spectrum of RNF5 substrates, the structural basis for its dual roles in different species, and its potential as a therapeutic target in viral infections and cancer .

How might combinations of targeting RNF5 with other therapeutic approaches enhance antiviral strategies?

The complex role of RNF5 in viral pathogenesis suggests potential synergistic effects when combining RNF5-targeted therapies with other antiviral approaches:

• Combination with direct-acting antivirals: RNF5 inhibitors could enhance the efficacy of direct-acting antivirals by simultaneously targeting viral replication and bolstering host antiviral immunity.

• Immune checkpoint modulation: Combining RNF5 inhibition with immune checkpoint inhibitors might enhance T cell responses against virus-infected cells.

• Interferon-based therapies: RNF5 inhibition could potentiate the effects of exogenous interferons by preventing the degradation of STING and MAVS, key components of interferon-inducing pathways.

• Broad-spectrum antiviral approach: Given RNF5's involvement in multiple viral life cycles, targeting it might provide a host-directed strategy effective against a range of viruses.

• Personalized therapy: Genetic variations in RNF5 or its regulators might predict responsiveness to RNF5-targeted therapies, enabling patient stratification.

The multifaceted roles of RNF5 in SARS-CoV-2 infection, particularly its involvement in viral assembly, budding, and release through K63-linked ubiquitination of the M protein, highlight its potential as part of combination therapies targeting different stages of the viral life cycle .